Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of the personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing the target regions from the extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from the tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy.

Abstract: The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).

Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.

Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, c) sequencing said target regions from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine. The invention is of very special interest in the field of personalized immunotherapy.

Abstract: The present invention is in the field of immunotherapy. The invention provides non-propagative viral vectors comprising a nucleic acid molecule encoding at least a polypeptide having an IL-7 activity, wherein said non-propagative viral vector is for use in the treatment of immune depression induced by sepsis, burn, trauma, major surgery, senescence and/or coronavirus.

Abstract: The present disclosure relates to a method for removing a non-target RNA from an RNA sample, including: performing reverse transcription on an RNA sample by using a reverse transcription primer, and removing an RNA template, to obtain a non-target first-strand cDNA and a target first-strand cDNA; hybridizing the non-target first-strand cDNA with a specific probe to obtain a non-target first-strand cDNA-probe complex; and digesting the non-target first-strand cDNA-probe complex by using a duplex-specific nuclease to obtain the target first-strand cDNA. The non-target first-strand cDNA-probe complex can be further extended to obtain a double-stranded DNA region that can be completely digested by the duplex-specific nuclease, then the duplex-specific nuclease is added for digestion.

Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.

Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising said oncolytic virus and said one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and said one or more immune checkpoint modulator(s).

Abstract: The present invention provides a combination comprising at least an oncolytic virus and one or more immune checkpoint modulator(s) for use for the treatment of a proliferative disease such as cancer. It also relates to a kit comprising an oncolytic virus and one or more immune checkpoint modulator(s) in separate containers. It also concerns a pharmaceutical composition comprising effective amount of an oncolytic virus and one or more immune checkpoint modulator(s).

Abstract: The present disclosure relates to a method for removing a non-target RNA from an RNA sample, including: performing reverse transcription on an RNA sample by using a reverse transcription primer, and removing an RNA template, to obtain a non-target first-strand cDNA and a target first-strand cDNA; hybridizing the non-target first-strand cDNA with a specific probe to obtain a non-target first-strand cDNA-probe complex; and digesting the non-target first-strand cDNA-probe complex by using a duplex-specific nuclease to obtain the target first-strand cDNA. The non-target first-strand cDNA-probe complex can be further extended to obtain a double-stranded DNA region that can be completely digested by the duplex-specific nuclease, then the duplex-specific nuclease is added for digestion.

Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.

Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.

Abstract: The present invention generally relates to a personalized cancer vaccine comprising a recombinant poxvirus encoding one or more neopeptide(s) or a composition comprising such a recombinant poxvirus and a pharmaceutically acceptable vehicle as well as the use of said personalized cancer vaccine for treating a cancerous subject in need thereof. A specific embodiment is directed to a method of providing such a vaccine or composition comprising an identification step comprising a) extracting the DNA from a tumor sample and a non-tumor sample, b) selecting target regions, preferably the entire coding regions of the genome (exome), c) sequencing said target regions (e.g. the exome) from said extracted DNAs and d) identifying one or more tumor-specific mutation(s) by comparing the DNA sequences obtained from said tumor and non-tumor samples. Embodiments also include a method of treating cancer or preventing its relapse comprising administration of such a personalized cancer vaccine.

Abstract: The present disclosure relates to a circular transposon compound, wherein the circular transposon compound includes a Tn5 transposase and an insert DNA; and the insert DNA contains transposon end sequences, two tag sequences, and a DNA sequence containing an enzymecutting site. The present disclosure further relates to an application of the circular transposon in DNA library construction. In the present disclosure, the method of constructing a DNA library by using the circular transposon compound has simple and convenient operations and high library construction efficiency, wherein the whole process of the library construction can be completed in only 80 minutes, and the required DNA amount is significantly reduced, with 1-50 ng of target DNAs being sufficient for the library construction, thereby promoting the wide application of the next-generation sequencing technology in the life science research and precise medical enterprise, which has great and profound significance.

Abstract: The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.

Abstract: The present invention relates to liquid formulations of poxvirus, in particular vaccinia virus, stable during storage. Such stable liquid formulations comprise a) a poxvirus, preferably a vaccinia virus, b) a pharmaceutically acceptable buffer, c) a monovalent salt, d) a pharmaceutically acceptable disaccharide or sugar alcohol, and e) a pharmaceutically acceptable chelating agent, wherein the pH of the formulation is comprised between 6.5 and 8.5.

Abstract: The present invention provides an immunotherapeutic composition for use in combination with one or more MDSC (Myeloid-derived suppressor cells) modulator(s) and a kit of parts comprising such components as well as methods using such components in combination. The invention also provides the use of Phosphodiesterase-5 (PDE5) inhibitors for reversing immunosuppression in chronic infectious diseases. The invention is of very special interest in treating or preventing diseases, especially chronic infectious diseases such as hepatitis B.

Abstract: The present invention relates to polymerase HBV mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to HBV with the goal of providing a protective or therapeutic effect against HBV infection.

Abstract: The present invention generally relates to an immunostimulatory combination comprising a first composition comprising a therapeutic vaccine and a second composition comprising one or more TLR9 ligand(s) such as CpG-containing oligonucleotide(s) as well as the use of such a first composition in combination with said second composition for treating a subject in need thereof. A specific embodiment is directed to the combination of a vectorized therapeutic vaccine encoding antigen(s) and a CpG-containing oligonucleotide such as Litenimod. Embodiments also include kits comprising such compositions as well as methods for treating, preventing or inhibiting diseases, in particular proliferative diseases or infectious diseases comprising administration of such first and second compositions.

Abstract: The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.